- Home Page
- Press Releases
- Research Insight
Uncover the Risks Associated with Anti-Bribery and Anti-Corruption, Data Privacy and HCP Engagement
Backed by 20 years of global compliance programming and education, CBI’s Pharmaceutical Compliance Congress (PCC) Asia is the premier event for compliance teams to gain novel approaches and advanced strategies for the quickly transforming regulatory landscape.
With rapidly evolving global regulations deeply affecting business operations in Asia, multi-national life sciences companies must be more attentive than ever. Increasing anti-bribery and anti-corruption requirements from the U.S., UK and local Asian regulatory bodies are driving compliance professionals to build and maintain effective compliance programs that not only meet these multi-jurisdictional requirements, but align with their overall business objectives.
This fully-packed two day forum features in-depth content and insights around the most important compliance and legal issues in China, South Korea, Japan, Indonesia, India, Thailand, Vietnam, Malaysia, the Philippines and Australia. Join the brightest minds and most influential stakeholders in life sciences compliance to benchmark, exchange strategies and learn about the latest guidance and laws, surrounding bribery and corruption, HCP engagement, transparency, data privacy, competition, intellectual property and more.